Patent for Humanetics cancer radiation drug

Minneapolis-based Humanetics Corporation said it has been awarded a US patent for its new drug, BIO 300, to be used in conjunction with current cancer treatments.

“BIO 300 is being developed to improve outcomes for cancer patients receiving radiation treatment for solid tumors,” said Humanetics.

“Up to 70% of all cancer patients with solid tumors will receive radiation treatment, and over half a million patients receive these treatments annually throughout the United States and Europe.

“Radiation treatment is designed to destroy a patient’s cancerous tumor, but it also may harm the normal tissue around the tumor or in the treatment path …

“BIO 300 has been shown to mitigate the harm to normal tissues, while also enhancing the ability of radiation to kill tumor cells.”

Dr. Michael Kaytor, Vice President of Research and Development at Humanetics, said: “BIO 300’s demonstrated efficacy to enhance cancer treatment while reducing treatment-related side effects is unprecedented.

“There are currently no drugs on the market that fill this critical need, and we’re very optimistic about BIO 300’s potential.

“This patent issuance is an important step in our progress.”